Today’s Daily Dose brings you news about Anika’s preliminary second quarter revenue; Asterias’ progress in SCiStar trial; CymaBay’s encouraging results from PBC trial; EDAP’s Focal One update; Ligand’s expanded license relationship with Amgen; Paratek’s encouraging results from OASIS-2 study; FDA approval of Puma’s breast cancer drug and Repros’ disappointment over the clinical program of oral Proellex.
Anika Therapeutics Inc. (ANIK) expects revenue growth for the second quarter of 2017 to be in the range of 23% to 26% year-over-year. The expected revenue includes $5 million milestone payment from U.S. commercial sales of MONOVISC, announced on Monday. The Company reported revenue of $26.6 million in Q2, 2016.
Anika is scheduled to report its second quarter 2017 financial results on July 26, 2017.
In a SEC filing dated July 13, 2017, Anika has revealed that it will pay a gross amount of $350 thousand to Stephen Mascioli for all alleged damages and attorneys’ fees. Stephen Mascioli was appointed to the role of Chief Medical Officer at Anika in April 2016, and according to reports, he left the Company in January 2017. The nature of allegations has not been disclosed.
ANIK closed Monday’s trading at $46.47, up 0.76%.
Asterias Biotherapeutics Inc. (AST) has completed enrollment and dosing of AIS-A 20 million cell cohort in its ongoing phase 1/2a clinical trial of AST-OPC1 for acute spinal cord injury, dubbed SCiStar.
In this cohort, five patients with AIS-A grade spinal cord injury were administered 20 million AST-OPC1 cells. The 20 million AST-OPC1 cell dose is the highest to be investigated in the SCiStar clinical trial. The company expects to report top-line six-month results from this cohort in January 2018.
AST closed Monday’s trading at $3.50, unchanged from the previous trading day’s close.
Shares of CymaBay Therapeutics Inc. (CBAY) were down more than 6% in extended trading on Monday, following its proposed public offering of common stock.
The Company has…